AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Gene Therapy Market Expected to Grow with a CAGR of 16.92% During the Forecast Period, 2019-2024 - ResearchAndMarkets.com

November 26, 2019

DUBLIN--(BUSINESS WIRE)--Nov 26, 2019--

The “Gene Therapy Market - Forecasts from 2019 to 2024” report has been added to ResearchAndMarkets.com’s offering.

The global gene therapy market is expected to grow at a CAGR of 16.92% reach $8.748 billion by 2024 from $3.425 billion in 2018.

Gene therapy is an experimental technique that involves the introduction of DNA usually containing a functional gene into a patient for the treatment of genetic disorders. Gene therapy works by replacing, repairing or repressing the mutated gene. Therefore, with the right target and approach, it can address the root cause of a severe disease where known genetic mutations lead to deficient or non-functional protein production or other related problems. The gene therapy may be a promising option for genetic diseases such as muscular dystrophy and cystic fibrosis.

The growth in the market may be attributed to the increase in awareness among the people regarding the benefits of gene therapy coupled with the increased funding activities for research and development of gene therapy by various governments. However, the high cost of gene therapy might restrain the growth of the market during the given forecast period. Problems with suppressing the immune responses due to the introduction of new genes may also hamper the market growth during the given time frame.

The Global Gene Therapy Market - Forecasts from 2019 to 2024 is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by Technique, Vector Type, Indication and geography.

Major players in the gene therapy market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the gene therapy market.

Key Topics Covered:

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the study

1.4. Currency

1.5. Assumptions

1.6. Base, and Forecast Years Timeline

2. Research methodology

2.1. Research Design

2.2. Secondary Sources

3. Executive Summary

4. Market Dynamics

4.1. Market Segmentation

4.2. Market Drivers

4.3. Market Restraints

4.4. Market Opportunities

4.5. Porter’s Five Forces Analysis

4.5.1. Bargaining Power of Suppliers

4.5.2. Bargaining Power of Buyers

4.5.3. Threat of New Entrants

4.5.4. Threat of Substitutes

4.5.5. Competitive Rivalry in the Industry

4.6. Life Cycle Analysis - Regional Snapshot

4.7. Market Attractiveness

5. Gene Therapy Market by Technique

5.1. Gene Augmentation

5.2. Gene Inhibition

5.3. Killing of specific cells

6. Gene Therapy Market by Vector Type

6.1. Viral Vectors

6.2. Non-Viral Vectors

7. Gene Therapy Market by Indication

7.1. Genetic Disorders

7.2. Cardiovascular

7.3. Oncology

7.4. Others

8. Gene Therapy Market by Geography

8.1. North America

8.1.1. USA

8.1.2. Canada

8.1.3. Mexico

8.2. South America

8.2.1. Brazil

8.2.2. Argentina

8.2.3. Others

8.3. Europe

8.3.1. UK

8.3.2. Germany

8.3.3. Italy

8.3.4. Spain

8.3.5. Others

8.4. Middle East and Africa

8.4.1. Israel

8.4.2. Saudi Arabia

8.4.3. Others

8.5. Asia Pacific

8.5.1. China

8.5.2. Japan

8.5.3. India

8.5.4. Australia

8.5.5. Others

9. Competitive intelligence

9.1. Competitive Benchmarking and Analysis

9.2. Strategies of Key Players

9.3. Recent Investments and Deals

10. Company Profile

10.1. Novartis

10.2. Amgen

10.3. Bluebird Bio

10.4. Glaxosmithkline

10.5. Shenzhen Sibiono Genetech

10.6. Spark Therapeutics

10.7. AveXis, Inc.

10.8. Chiesi Farmaceutici

10.9. Alnylam

For more information about this report visit https://www.researchandmarkets.com/r/vcck48

View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005557/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENETICS

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/26/2019 09:43 AM/DISC: 11/26/2019 09:43 AM

http://www.businesswire.com/news/home/20191126005557/en